Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

S Sathornsumetee, A Desjardins… - Neuro …, 2010 - academic.oup.com
Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR)
signaling are established contributors to malignant glioma (MG) biology. We, therefore …
被引用次数：261 相关文章
[PDF] academia.edu

[PDF][PDF] Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

S Sathornsumetee, A Desjardins, JJ Vredenburgh… - Neuro …, 2010 - academia.edu
Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR)
signaling are established contributors to malignant glioma (MG) biology. We, therefore …
[HTML] nih.gov

[HTML][HTML] Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

S Sathornsumetee, A Desjardins, JJ Vredenburgh… - Neuro …, 2010 - ncbi.nlm.nih.gov
Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR)
signaling are established contributors to malignant glioma (MG) biology. We, therefore …

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.

S Sathornsumetee, A Desjardins, JJ Vredenburgh… - Neuro …, 2010 - europepmc.org
Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR)
signaling are established contributors to malignant glioma (MG) biology. We, therefore …

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

S Sathornsumetee, A Desjardins… - Neuro …, 2010 - pubmed.ncbi.nlm.nih.gov
Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR)
signaling are established contributors to malignant glioma (MG) biology. We, therefore …

[引用][C] Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

S SATHOMSUMETEE - Neuro Oncol, 2010 - cir.nii.ac.jp

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

S Sathornsumetee, A Desjardins… - Neuro …, 2010 - mahidol.elsevierpure.com
Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR)
signaling are established contributors to malignant glioma (MG) biology. We, therefore …
[PDF] researchgate.net

[PDF][PDF] Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

S Sathornsumetee, A Desjardins… - Neuro …, 2010 - researchgate.net
Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR)
signaling are established contributors to malignant glioma (MG) biology. We, therefore …

[引用][C] Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

S Sathornsumetee, A Desjardins, JJ Vredenburgh… - Neuro-Oncology, 2010 - cir.nii.ac.jp

[引用][C] Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

S Sathornsumetee, A Desjardins… - Neuro …, 2010 - Oxford University Press